- Home
- MCRI vs KNSA Comparison
MCRI vs KNSA Comparison
Compare MCRI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- KNSA
- Stock Information
- Founded
- MCRI 1972
- KNSA 2015
- Country
- MCRI United States
- KNSA United Kingdom
- Employees
- MCRI N/A
- KNSA N/A
- Industry
- MCRI Hotels/Resorts
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- KNSA Health Care
- Exchange
- MCRI Nasdaq
- KNSA Nasdaq
- Market Cap
- MCRI 1.9B
- KNSA 1.9B
- IPO Year
- MCRI 1993
- KNSA 2018
- Fundamental
- Price
- MCRI $104.33
- KNSA $33.49
- Analyst Decision
- MCRI Hold
- KNSA Strong Buy
- Analyst Count
- MCRI 5
- KNSA 6
- Target Price
- MCRI $96.20
- KNSA $40.83
- AVG Volume (30 Days)
- MCRI 78.8K
- KNSA 517.5K
- Earning Date
- MCRI 10-22-2025
- KNSA 10-28-2025
- Dividend Yield
- MCRI 1.15%
- KNSA N/A
- EPS Growth
- MCRI N/A
- KNSA N/A
- EPS
- MCRI 4.22
- KNSA 0.07
- Revenue
- MCRI $534,693,999.00
- KNSA $529,332,000.00
- Revenue This Year
- MCRI $6.80
- KNSA $37.21
- Revenue Next Year
- MCRI $4.13
- KNSA $11.99
- P/E Ratio
- MCRI $24.75
- KNSA $518.13
- Revenue Growth
- MCRI 4.65
- KNSA 56.18
- 52 Week Low
- MCRI $69.99
- KNSA $17.82
- 52 Week High
- MCRI $113.88
- KNSA $34.55
- Technical
- Relative Strength Index (RSI)
- MCRI 61.59
- KNSA 60.98
- Support Level
- MCRI $100.02
- KNSA $32.89
- Resistance Level
- MCRI $106.75
- KNSA $34.16
- Average True Range (ATR)
- MCRI 2.21
- KNSA 0.80
- MACD
- MCRI 0.09
- KNSA -0.15
- Stochastic Oscillator
- MCRI 75.68
- KNSA 57.52
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.